The manufacturer only withdraws the approved treatment for preterm birth from the market due to a lack of confirmatory data

The manufacturer only withdraws the approved treatment for preterm birth from the market due to a lack of confirmatory data

Hydroxyprogesterone caproate injection (Makena; Covis Pharma Group) was voluntarily withdrawn from the market after the FDA’s Advisory Committee on Obstetric, Reproductive and Urological Drugs decided that a confirmatory study showed …

Read more